Navigation Links
Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
Date:12/11/2011

to take hydroxyurea.

Follow-Up Study I data indicate that children who continue to take hydroxyurea have statistically lower rates of pain crises requiring emergency room visits, episodic transfusions, and hospital admissions for any reason when compared to those taking placebo. These clinical benefits are similar to those demonstrated by the drug in BABY HUG, the results of which were published earlier this year and are consistent with previously published trials that detail the therapy's benefits in older children and adults.

"Our study data reveal not only that the clinical benefits of hydroxyurea continue with ongoing administration, but also the wide acceptance of the treatment by the families of our patients, demonstrated by the high percentage of families that continued their children on hydroxyurea after the randomized trial ended," said lead author Zora R. Rogers, MD, Professor of Pediatrics at UT Southwestern Medical Center Dallas and Clinical Director of the Bone Marrow Failure and General Hematology Program at Children's Medical Center Dallas. "Analysis of growth and development assessments obtained in the Follow-Up Study along with these clinical results will further enhance our understanding of the benefits of the use of starting hydroxyurea in children with sickle cell disease at a very young age."

The BABY HUG Follow-Up Study I is funded by the National Heart, Lung, and Blood Institute (NHLBI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Dr. Rogers will present this study in an oral presentation on Sunday, December 11, at 4:30 p.m. PST at the Manchester Grand Hyatt in the Elizabeth Ballroom AB.

Genotoxicity Associated with Hydroxyurea Exposure in Infants with Sickle Cell Anemia: Results From the BABY-HUG Phase III Clinical Trial [Abstract 8]

Using data from the larg
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
2. OpenClinica EDC Solution Deployed for Retina Implant Studies
3. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
4. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
5. NIST studies how new helium ion microscope measures up
6. Five New Clinical Studies Show Value of Masimo PVI & PI
7. ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting
8. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
9. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
10. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
11. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Fennec Pharmaceuticals, Inc. ... positive interim results from a poster presented today ... label randomised phase III trial of the efficacy ... patients receiving cisplatin (Cis) monotherapy for standard risk ... American Society of Clinical Oncology (ASCO) 2015 Annual ...
(Date:6/1/2015)... Minn. and SOUTH SAN FRANCISCO, ... Ventures, the venture arm of Baxter International Inc. (NYSE: ... Development, LLC ("VPD") today announced the formation of Vitesse ... initiated by Baxter Ventures to focus on the development ... immunology, hematology, and oncology. Following the spin-off of Baxter ...
(Date:6/1/2015)... June 1, 2015 Esperance Pharmaceuticals Inc. today ... lead candidate EP-100 in ovarian cancer patients resistant to ... seek and destroy cancer cells that overexpress luteinizing hormone-releasing ... over-expressed in a wide range of cancers. ... trial of EP-100 were presented at the 2015 ...
(Date:6/1/2015)... 29, 2015 Research and Markets ... of the "2015 Strategies in European ... their offering. This new 273-page ... diagnostic market, including emerging tests, technologies, instrumentation, ... of leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... 30, 2011 Current Ceo Rudi Pauwels ... , New Ceo   Appointment Strengthens ... Of Its   First Product In 2013 ... diagnostic (MDx) systems designed to drive personalized medicine and ...
... Nov. 30, 2011  DiaTech Life Sciences has announced the ... use of the Microculture Kinetic (MiCK) assay for ... chemotherapy is most effective for cancer patients. DiaTech has ... developed a model to assist pharmaceutical companies in validating ...
... today that Lex Van der Ploeg, PhD, has joined ... Ploeg brings to Rhythm more than 25 years of ... therapeutic areas. "Lex has considerable experience with ... are targeting with our ghrelin and melanocortin 4 receptor ...
Cached Biology Technology:Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer 2Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer 3Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer 4DiaTech Life Sciences Announces Medical Advisory Board 2DiaTech Life Sciences Announces Medical Advisory Board 3Rhythm Names Lex Van der Ploeg Chief Scientific Officer 2
(Date:5/11/2015)... -- Through a well-rounded UAS delegation representing private industry, government, and ... at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people from ... UAS ecosystem. "Our message is clear and ... Rich Knoll . "If you want to fly UAS, ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an order for ... World Peace Industrial Group (WPI), part of WPG Holdings. WPI ... . Deliveries are planned to take place during Q3 2015 ... China . The order value of 235 ... 1 000 MSEK for 2015.   Jörgen Lantto, acting ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... the most common type of lung cancer are notoriously ... to the cellular pathways that regulate responses to cisplatin ... 26th in the journal Cell Reports . The ... to predict how these patients will respond to chemotherapy, ...
... Hole Oceanographic Institution (WHOI) researchers have partnered with ... developed at WHOI: the Imaging FlowCytobot, an automated ... that uses light to provide wireless transmission of ... time. WHOI biologists Robert Olson and Heidi ...
... University of Leeds and the Chinese Academy of Sciences have ... next generation energy storage systems. Finding more effective and ... deal with the problem of peak demand on electricity grids. ... solar generation is also a pressing problem. People use ...
Cached Biology News:New biomarker for common lung cancer predicts responses to chemotherapy 2WHOI scientists/engineers partner with companies to market revolutionary new instruments 2WHOI scientists/engineers partner with companies to market revolutionary new instruments 3WHOI scientists/engineers partner with companies to market revolutionary new instruments 4University of Leeds and Chinese Academy of Sciences join forces 2University of Leeds and Chinese Academy of Sciences join forces 3
Request Info...
Bovine Serum Albumin Peroxidase Stabilizer Solution, 1 L...
SAIVI Alexa Fluor 680 injectable contrast agent *bovine serum albumin*...
... Lysate contains the cellular components necessary for ... elongation and termination factors) but has not ... is used primarily for the isolation of ... of endogenous globin mRNA. Untreated Lysate is ...
Biology Products: